Scarica l'app Stockscreener
19.55
1.98%
0.3695
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.18
Aprire:
$19.27
Volume 24 ore:
1.58M
Relative Volume:
0.51
Capitalizzazione di mercato:
$2.07B
Reddito:
$2.18B
Utile/perdita netta:
$-64.32M
Rapporto P/E:
-20.28
EPS:
-0.9641
Flusso di cassa netto:
$91.18M
1 W Prestazione:
+8.85%
1M Prestazione:
+24.19%
6M Prestazione:
-16.62%
1 anno Prestazione:
+12.93%
Intervallo 1D:
$18.63
$19.75
Intervallo di 1 settimana:
$17.45
$19.75
Portata 52W:
$10.41
$25.32
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Nome
Sarepta Therapeutics Inc
Settore
Industria
Telefono
617-274-4000
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
19.56 | 2.02B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
522.00 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.13 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.99 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2025-12-09 | Iniziato | Wedbush | Outperform |
| 2025-11-05 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-09-22 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Iniziato | Bernstein | Mkt Perform |
| 2025-07-29 | Reiterato | H.C. Wainwright | Sell |
| 2025-07-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Iniziato | Citigroup | Sell |
| 2025-07-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-07-21 | Downgrade | Needham | Hold → Underperform |
| 2025-07-21 | Downgrade | UBS | Buy → Neutral |
| 2025-07-18 | Downgrade | Needham | Buy → Hold |
| 2025-06-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Downgrade | TD Cowen | Buy → Hold |
| 2025-06-17 | Iniziato | Wolfe Research | Peer Perform |
| 2025-06-16 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-06-16 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Downgrade | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Iniziato | Wells Fargo | Overweight |
| 2025-04-02 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-11-27 | Reiterato | Needham | Buy |
| 2024-11-25 | Iniziato | H.C. Wainwright | Sell |
| 2024-11-07 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-07-29 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-13 | Ripresa | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-21 | Iniziato | Wedbush | Outperform |
| 2023-10-31 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-04 | Iniziato | Citigroup | Buy |
| 2023-03-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Reiterato | BTIG Research | Buy |
| 2022-12-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Reiterato | Needham | Buy |
| 2021-12-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-08-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-01-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-11 | Downgrade | UBS | Buy → Neutral |
| 2021-01-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Iniziato | Mizuho | Buy |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-08-21 | Reiterato | Needham | Buy |
| 2019-07-09 | Reiterato | Morgan Stanley | Overweight |
| 2019-07-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-11 | Reiterato | Credit Suisse | Outperform |
| 2018-10-12 | Iniziato | Bernstein | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Reiterato | RBC Capital Mkts | Outperform |
| 2018-09-14 | Ripresa | BofA/Merrill | Buy |
| 2018-09-06 | Iniziato | Credit Suisse | Outperform |
| 2018-08-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Reiterato | Robert W. Baird | Outperform |
| 2018-06-20 | Reiterato | Needham | Buy |
| 2018-06-19 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Enterprise value to EBITDA forward of Sarepta Therapeutics, Inc. – LSE:0L35 - TradingView
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® - Sarepta Therapeutics
Sarepta Refused FDA’s Request to Halt Elevidys Shipments - MSN
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Trading Systems Reacting to (SRPT) Volatility - Stock Traders Daily
SRPTSarepta Therapeutics Inc Volatility & Greeks - Finviz
ETFs Investing in Sarepta Therapeutics, Inc. Stocks - TradingView
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Sarepta Therapeutics Jumps 6.5% Amid Sector-Wide Rally - AlphaStreet
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs - Sahm
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail - BioSpace
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5 - Moomoo
SRPT Stock Quote Price and Forecast - CNN
SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
FDA Accepts sNDAs for Sarepta's AMONDYS 45 and VYONDYS 53, Targeting Traditional Approval in Duchenne - BioPharm International
FDA Accepts Sarepta's Applications for Full Approval of Two DMD Treatments - Intellectia AI
SRPT Stock Climbs After Sarepta Seeks Permanent FDA Nod For Two Duchenne Therapies - Stocktwits
Mizuho reiterates Sarepta stock rating after FDA filing acceptance By Investing.com - Investing.com Canada
Why is Sarepta Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Sarepta stock jumps as FDA accepts DMD drug applications - Investing.com UK
Sarepta stock jumps as FDA accepts DMD drug applications By Investing.com - Investing.com Nigeria
Sarepta (SRPT) Seeks Traditional Approval for Duchenne Therapies - GuruFocus
FDA accepts Sarepta filings for two Duchenne therapies - Investing.com
FDA accepts Sarepta filings for two Duchenne therapies By Investing.com - Investing.com Canada
FDA to review Sarepta’s Duchenne drugs, with decision due Feb. 28, 2027 - Stock Titan
Sarepta Therapeutics (SRPT) Following FDA Filings And The Case For A Reset Valuation - Sahm
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from Russell 1000 Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Value Benchmark - marketscreener.com
Sarepta Therapeutics (SRPT) Stock Analysis: Unveiling a 30% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) added to Russell 2000 Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS: SRPT) dropped from Russell 1000 Dynamic Index - marketscreener.com
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) dropped from Russell Midcap Value Benchmark - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutic - The National Law Review
Investors SueWallSt as Sarepta Therapeutics, Inc. Faces Securities Fraud Allegations - The National Law Review
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Did You Lose Money on Sarepta Therapeutics, Inc. (SRPT)? Levi & K - The National Law Review
Class Action Lawsuit Filed: Sarepta Therapeutics, Inc. (SRPT) – Join by August 25, 2025Contact Levi & Korsinsky - The National Law Review
Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025Sarepta Therapeutics, Inc. (SRPT) - The National Law Review
Class Action Lawsuit Filed Against Sarepta Therapeutics, Inc. (SR - The National Law Review
Sarepta Therapeutics Rises As Gene Therapy Outlook Strengthens - StocksToTrade
SRPT Rises As Sarepta Gains Gene Therapy Momentum - timothysykes.com
SRPT Jumps As Sarepta Wins Tailwinds In Gene Therapy - StocksToTrade
Sarepta Therapeutics Stock Firms As Gene Therapy Tailwinds Build - timothysykes.com
Sarepta Therapeutics, Inc. Actuals & Estimates (BMV:SRPT) - TradingView
Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):